Welcome to our dedicated page for Akari Therapeutics news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics stock.
Akari Therapeutics plc develops oncology antibody-drug conjugates built around RNA splicing modulator payloads. News about AKTX centers on its ADC platform, the PH1 payload technology, and lead program AKTX-101, a TROP2-targeted ADC studied in solid tumor models including bladder, lung and breast cancer. Updates also cover intellectual-property protection for the company’s payload chemistry and therapeutic applications.
Recurring company developments include preclinical data releases, oncology conference abstracts, strategic development collaborations, capital-structure disclosures, governance matters, and American Depositary Share program updates. As an ADR issuer, Akari’s news may also address ordinary-share and ADS mechanics tied to Nasdaq listing requirements and shareholder approvals.
Akari Therapeutics (Nasdaq: AKTX) announced an abstract accepted for a poster at the American Association for Cancer Research Annual Meeting 2026, April 17–22, 2026.
The poster, "Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast," will be presented April 20, 2026, 2:00–5:00 PM PT in Poster Section 19 and posted online after 5:00 PM PT.
Akari Therapeutics (Nasdaq: AKTX) will change its American Depositary Share ratio from 1 ADS = 2,000 ordinary shares to 1 ADS = 80,000 ordinary shares, effective March 31, 2026. ADS holders must exchange every forty ADSs for one new ADS.
Deutsche Bank will arrange the exchange, no fractional new ADSs will be issued, and fractional entitlements will be aggregated, sold, and distributed in cash (net of fees). Akari said the change aims to help maintain Nasdaq minimum bid price compliance and cautioned it cannot assure post-change ADS price performance.
Akari Therapeutics (Nasdaq: AKTX) released a CEO Corner from Abizer Gaslightwala reviewing his first year and strategic progress toward clinical development.
Highlights include advancement of the PH1 ADC payload platform, lead program AKTX-101 (Trop2-targeted) with a non-cleavable linker, initiation of IND-enabling activities with WuXi XDC, a target IND/CTA filing goal in late 2026 or early 2027, introduction of AKTX-102 targeting CEACAM5, multiple provisional patent filings, and formation of a scientific advisory group.
Akari Therapeutics (Nasdaq: AKTX) appointed Prafulla Gokhale, Ph.D., to its Scientific Advisory Board on Feb 26, 2026. Dr. Gokhale brings 20 years in preclinical oncology, RNA biology and translational therapeutics to support advancement of AKTX-101 and the company’s PH1 spliceosome-modulating payload toward first-in-human studies.
His experience directing translational programs and integrating genomics, patient-derived models and imaging is expected to refine AKTX-101's clinical strategy and translational experiments.
Akari Therapeutics (Nasdaq: AKTX) appointed Olga Anczukow, Ph.D., to its Scientific Advisory Board on February 23, 2026. Dr. Anczukow is an internationally recognized RNA biology and cancer researcher with roles at The Jackson Laboratory and University of Connecticut.
The appointment reinforces Akari's focus on advancing its PH1 ADC payload that targets RNA splicing in cancer cells and aims to strengthen translational research and scientific strategy.
Akari Therapeutics (Nasdaq: AKTX) announced that CEO Abizer Gaslightwala will present in person at the 2026 Biocom Global Partnering & Investor Conference.
The presentation is scheduled for Wednesday, February 25, 2026 at 11:00 AM PST in Track B, and management will be available for one-on-one meetings with registered investors.
Akari Therapeutics (Nasdaq: AKTX) CEO Abizer Gaslightwala joined a Virtual Investor “What This Means” interview on Feb. 11, 2026 to discuss the company’s expanded ADC pipeline, a recent patent filing, and the introduction of second ADC candidate AKTX-102 targeting CEACAM5 tumors.
The segment reviewed the scalability of Akari’s PH1-powered ADC platform, the company’s differentiated CEACAM5 antibody construct, execution priorities for lead program AKTX-101 as it advances toward IND and CTA submissions, and the strategic role of a growing patent estate to support partnering and long-term value creation.
Akari Therapeutics (Nasdaq: AKTX) will present a live video webcast on Tuesday, February 10, 2026 at 1:00 PM EST as part of Webull Financial’s Corporate Connect Webinar Series.
CEO Abizer Gaslightwala will provide a corporate overview of Akari’s ADC platform, the proprietary PH1 spliceosome‑modulating payload, lead program AKTX‑101 (Trop2‑targeting ADC), IND‑enabling activities toward a first‑in‑human trial in late 2026 or early 2027, and a brief update on AKTX‑102.
Akari Therapeutics (NASDAQ: AKTX) filed U.S. provisional patent No. 63/958,508 for AKTX-102, a CEACAM5-targeted ADC that pairs a novel antibody construct with Akari’s PH1 spliceosome payload.
The filing claims composition-of-matter protection for antibody design and ADC constructs and expands Akari’s PH1 patent family. CEACAM5 expression cited: 80–90% of gastrointestinal cancers, ~30% bladder, 25% lung adenocarcinomas, up to 50% luminal A breast. Akari plans IND-enabling work for AKTX-101 with FDA interactions in H1 2026 and aims for IND/CTA submission end-2026/early-2027.
Akari Therapeutics (Nasdaq: AKTX) released a CEO Corner featuring CEO Abizer Gaslightwala summarizing 2025 progress and steps toward a clinical transition in 2026. The update highlights advancement of a novel ADC payload platform built on the proprietary PH1 spliceosome‑modulating payload, described as having a dual mechanism of direct tumor cytotoxicity plus immune activation and a compelling preclinical efficacy and safety profile. In 2025 the company announced a strategic manufacturing partnership with WuXi Biologics and began CMC and pre‑filing activities to support clinical readiness. Akari plans to initiate a First‑in‑Human trial as early as the end of 2026.